PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Resveratrol from R. japonica significantly improves gait score and synovitis in rat models and inhibits MSU-induced peritoneal inflammation [PMID:34335041]
A systematic review was conducted to evaluate the effect of R. japonica as a single herb or in formulas for RTIs [PMID:35281919]
Luteolin from R. japonica protects against acute lung injury by inhibiting macrophage apoptosis and mitochondrial damage via AKT1 [PMID:41046083]
A 70% ethanolic extract of the rhizome bark showed a statistically significant antiviral effect against wild-type SARS-CoV-2 in vitro [PMID:36134975]
R. japonica is identified as a single medicine effective for lowering uric acid [PMID:37193181]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 34335041 (2021) — Resveratrol Relieves Gouty Arthritis by Promoting Mitophagy to Inhibit Activation of NLRP3 Inflammasomes. · Journal of inflammation research
- 2.PMID: 35281919 (2022) — Reynoutria japonica Houtt for Acute Respiratory Tract Infections in Adults and Children: A Systematic Review. · Frontiers in pharmacology
- 3.PMID: 35009007 (2021) — Allelopathy of Knotweeds as Invasive Plants. · Plants (Basel, Switzerland)
- 4.PMID: 34961091 (2021) — New Approaches on Japanese Knotweed (Fallopia japonica) Bioactive Compounds and Their Potential of Pharmacological and Beekeeping Activities: Challenges and Future Directions. · Plants (Basel, Switzerland)
- 5.PMID: 39993002 (2025)